Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Pediatric Drugs
IF
1.76
Papers
982
Papers 996
1 page of 100 pages (996 results)
Newest
Published in Pediatric Drugs 1.76
Yahiya Y. Syed9
Estimated H-index: 9
(Springer Science+Business Media)
Hexyon® is a fully-liquid, ready-to-use, hexavalent vaccine approved in the EU since 2013 for primary and booster vaccination in infants and toddlers from age 6 weeks against diphtheria, tetanus, pertussis, hepatitis B (HB), poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib). While the source of HB antigen in Hexyon® is different from other vaccines, the rest of its valences have been extensively used in other approved vaccines. Hexyon® is highly immunogenic for a...
Published in Pediatric Drugs 1.76
Kathryn E. Kyler1
Estimated H-index: 1
(UMKC: University of Missouri–Kansas City),
Jonathan Wagner3
Estimated H-index: 3
(UMKC: University of Missouri–Kansas City)
+ -3 AuthorsValentina Shakhnovich4
Estimated H-index: 4
(UMKC: University of Missouri–Kansas City)
Obesity rates continue to rise in children, and little guidance exists regarding the need for adjustment away from total body weight-based doses for those prescribing drugs to this population of children. A majority of drugs prescribed to children with obesity result in either sub-therapeutic or supra-therapeutic concentrations, placing these children at risk for treatment failure and drug toxicities. In this review, we highlight available obesity-specific pharmacokinetic and dosing information ...
Published in Pediatric Drugs 1.76
Janet Sultana11
Estimated H-index: 11
(UNIME: University of Messina),
Cosimo Zaccaria3
Estimated H-index: 3
(European Medicines Agency)
+ -3 AuthorsCarmen Ferrajolo13
Estimated H-index: 13
Published on Jul 1, 2019in Pediatric Drugs 1.76
Iqbal Multani (Royal Children's Hospital), Jamil Manji (Royal Children's Hospital)+ 2 AuthorsKerr Graham9
Estimated H-index: 9
(University of Melbourne)
During the past 25 years, botulinum toxin type A (BoNT-A) has become the most widely used medical intervention in children with cerebral palsy. In this review we consider the gaps in our knowledge in the use of BoNT-A and reasons why muscle morphology and function in children with cerebral palsy are impaired. We review limitations in our knowledge regarding the mechanisms underlying the development of contractures and the difficulty in preventing them. It is clear from this review that injection...
Published on Jun 28, 2019in Pediatric Drugs 1.76
Edwin Liu , Deanne Dilley4
Estimated H-index: 4
(UCB)
+ 2 AuthorsTony Daniels1
Estimated H-index: 1
(UCB)
Objective This trial evaluated the short-term safety and tolerability, steady-state pharmacokinetics, and preliminary efficacy of brivaracetam oral solution in children aged 1 month to < 16 years with epilepsy.
Published on Jul 19, 2019in Pediatric Drugs 1.76
Amelia Licari15
Estimated H-index: 15
(UNIPV: University of Pavia),
Sara Manti12
Estimated H-index: 12
(UNIME: University of Messina)
+ 4 AuthorsGian Luigi Marseglia21
Estimated H-index: 21
(UNIPV: University of Pavia)
Severe asthma in children remains a significant issue. It places a heavy burden on affected individuals and society as a whole in terms of high morbidity, mortality, consumption of healthcare resources, and side effects from high-dose corticosteroid therapy. New, targeted biologic therapies for asthma have emerged as effective add-on options, complementing our expanding understanding of asthma phenotypes/endotypes and the underlying immunopathology of the disease spectrum. They include omalizuma...
Published in Pediatric Drugs 1.76
Henry L. Nguyen1
Estimated H-index: 1
(Mayo Clinic),
Katelyn R. Anderson2
Estimated H-index: 2
(Mayo Clinic),
Megha M. Tollefson13
Estimated H-index: 13
(Mayo Clinic)
Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new therapies that target specific pathways with increased efficacy and the potential for less systemic side...
Published on Jun 10, 2019in Pediatric Drugs 1.76
Nicola Pietrafusa4
Estimated H-index: 4
(Boston Children's Hospital),
Alessandro Ferretti (Boston Children's Hospital)+ 7 AuthorsNicola Specchio29
Estimated H-index: 29
(Boston Children's Hospital)
Background A pharmaceutical grade formulation of cannabidiol (CBD) has been approved for the treatment of Dravet syndrome and Lennox-Gastaut syndrome; however, this formulation is not yet available to patients outside the USA. In addition, CBD is thought to have broad anti-seizure properties that may be beneficial for other types of intractable epilepsy.
12345678910